148 related articles for article (PubMed ID: 31501191)
1. Genetic Variants Implicate Dual Oxidase-2 in Familial and Sporadic Nonmedullary Thyroid Cancer.
Bann DV; Jin Q; Sheldon KE; Houser KR; Nguyen L; Warrick JI; Baker MJ; Broach JR; Gerhard GS; Goldenberg D
Cancer Res; 2019 Nov; 79(21):5490-5499. PubMed ID: 31501191
[TBL] [Abstract][Full Text] [Related]
2. Clinical and Genetic Features of a Large Monocentric Series of Familial Non-Medullary Thyroid Cancers.
Cirello V; Colombo C; Karapanou O; Pogliaghi G; Persani L; Fugazzola L
Front Endocrinol (Lausanne); 2020; 11():589340. PubMed ID: 33488516
[TBL] [Abstract][Full Text] [Related]
3. FOXE1 polymorphisms are associated with familial and sporadic nonmedullary thyroid cancer susceptibility.
Tomaz RA; Sousa I; Silva JG; Santos C; Teixeira MR; Leite V; Cavaco BM
Clin Endocrinol (Oxf); 2012 Dec; 77(6):926-33. PubMed ID: 22882326
[TBL] [Abstract][Full Text] [Related]
4. Clinical features and genetic predisposition to hereditary nonmedullary thyroid cancer.
Vriens MR; Suh I; Moses W; Kebebew E
Thyroid; 2009 Dec; 19(12):1343-9. PubMed ID: 20001717
[TBL] [Abstract][Full Text] [Related]
5. Familial nonmedullary thyroid cancer: screening, clinical, molecular and genetic findings.
Navas-Carrillo D; Ríos A; Rodríguez JM; Parrilla P; Orenes-Piñero E
Biochim Biophys Acta; 2014 Dec; 1846(2):468-76. PubMed ID: 25218916
[TBL] [Abstract][Full Text] [Related]
6. The FOXE1 locus is a major genetic determinant for familial nonmedullary thyroid carcinoma.
Bonora E; Rizzato C; Diquigiovanni C; Oudot-Mellakh T; Campa D; Vargiolu M; Guedj M; ; McKay JD; Romeo G; Canzian F; Lesueur F
Int J Cancer; 2014 May; 134(9):2098-107. PubMed ID: 24127282
[TBL] [Abstract][Full Text] [Related]
7. Clinical behavior and genetics of nonsyndromic, familial nonmedullary thyroid cancer.
Bauer AJ
Front Horm Res; 2013; 41():141-8. PubMed ID: 23652675
[TBL] [Abstract][Full Text] [Related]
8. CHEK2 germline variants identified in familial nonmedullary thyroid cancer lead to impaired protein structure and function.
Pires C; Marques IJ; Valério M; Saramago A; Santo PE; Santos S; Silva M; Moura MM; Matos J; Pereira T; Cabrera R; Lousa D; Leite V; Bandeiras TM; Vicente JB; Cavaco BM
J Biol Chem; 2024 Mar; 300(3):105767. PubMed ID: 38367672
[TBL] [Abstract][Full Text] [Related]
9. HABP2 G534E Mutation in Familial Nonmedullary Thyroid Cancer.
Zhang T; Xing M
J Natl Cancer Inst; 2016 Jun; 108(6):djv415. PubMed ID: 26832773
[TBL] [Abstract][Full Text] [Related]
10. An update on familial nonmedullary thyroid cancer.
Ammar SA; Alobuia WM; Kebebew E
Endocrine; 2020 Jun; 68(3):502-507. PubMed ID: 32162184
[TBL] [Abstract][Full Text] [Related]
11. An evidence-based approach to familial nonmedullary thyroid cancer: screening, clinical management, and follow-up.
Sippel RS; Caron NR; Clark OH
World J Surg; 2007 May; 31(5):924-33. PubMed ID: 17429563
[TBL] [Abstract][Full Text] [Related]
12. HABP2 germline variants are uncommon in familial nonmedullary thyroid cancer.
Weeks AL; Wilson SG; Ward L; Goldblatt J; Hui J; Walsh JP
BMC Med Genet; 2016 Aug; 17(1):60. PubMed ID: 27530615
[TBL] [Abstract][Full Text] [Related]
13. Identification of susceptibility gene mutations associated with the pathogenesis of familial nonmedullary thyroid cancer.
Zhu J; Wu K; Lin Z; Bai S; Wu J; Li P; Xue H; Du J; Shen B; Wang H; Liu Y
Mol Genet Genomic Med; 2019 Dec; 7(12):e1015. PubMed ID: 31642198
[TBL] [Abstract][Full Text] [Related]
14. Clinical characteristics and outcome of familial nonmedullary thyroid cancer: a retrospective controlled study.
Robenshtok E; Tzvetov G; Grozinsky-Glasberg S; Shraga-Slutzky I; Weinstein R; Lazar L; Serov S; Singer J; Hirsch D; Shimon I; Benbassat C
Thyroid; 2011 Jan; 21(1):43-8. PubMed ID: 20954815
[TBL] [Abstract][Full Text] [Related]
15. Germline HABP2 Mutation Causing Familial Nonmedullary Thyroid Cancer.
Gara SK; Jia L; Merino MJ; Agarwal SK; Zhang L; Cam M; Patel D; Kebebew E
N Engl J Med; 2015 Jul; 373(5):448-55. PubMed ID: 26222560
[TBL] [Abstract][Full Text] [Related]
16. Identification of somatic TERT promoter mutations in familial nonmedullary thyroid carcinomas.
Marques IJ; Moura MM; Cabrera R; Pinto AE; Simões-Pereira J; Santos C; Menezes FD; Montezuma D; Henrique R; Rodrigues Teixeira M; Leite V; Cavaco BM
Clin Endocrinol (Oxf); 2017 Oct; 87(4):394-399. PubMed ID: 28502101
[TBL] [Abstract][Full Text] [Related]
17. Segregation and expression analyses of hyaluronan-binding protein 2 (HABP2): insights from a large series of familial non-medullary thyroid cancers and literature review.
Colombo C; Muzza M; Proverbio MC; Ercoli G; Perrino M; Cirello V; Vicentini L; Ferrero S; Fugazzola L
Clin Endocrinol (Oxf); 2017 Jun; 86(6):837-844. PubMed ID: 28222214
[TBL] [Abstract][Full Text] [Related]
18. Identification of a novel germline FOXE1 variant in patients with familial non-medullary thyroid carcinoma (FNMTC).
Pereira JS; da Silva JG; Tomaz RA; Pinto AE; Bugalho MJ; Leite V; Cavaco BM
Endocrine; 2015 May; 49(1):204-14. PubMed ID: 25381600
[TBL] [Abstract][Full Text] [Related]
19. The T1799A BRAF mutation is not a germline mutation in familial nonmedullary thyroid cancer.
Xing M
Clin Endocrinol (Oxf); 2005 Sep; 63(3):263-6. PubMed ID: 16117812
[TBL] [Abstract][Full Text] [Related]
20. Familial nonmedullary thyroid cancer: a review of the genetics.
Khan A; Smellie J; Nutting C; Harrington K; Newbold K
Thyroid; 2010 Jul; 20(7):795-801. PubMed ID: 20465534
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]